Form 4: Senti Biosciences Director Edward Mathers Receives Stock Option Grant

Senti Biosciences, Inc. Director and 10% Owner Edward T. Mathers was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting.

Summary

• Edward T. Mathers, a Director and 10% Owner of Senti Biosciences, Inc. (SNTI), was granted 21,950 stock options.
• The stock options have an exercise price of $2.05 per share.
• The grant date for these options was June 25, 2025, and they are set to expire on June 24, 2035.
• 100% of the shares underlying this option will vest upon the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the 2026 Annual Meeting, contingent on Mr. Mathers' continued service.
• This transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value creation, generally viewed as a positive or neutral development depending on the size relative to total compensation and company performance.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which demonstrates a pre-planned and transparent approach to insider equity transactions.

Future Outlook

The vesting schedule of the stock options implies an expectation of Edward T. Mathers' continued service to Senti Biosciences, Inc. through at least the first anniversary of the grant date or the 2026 Annual Meeting.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and broader corporate sectors, serving as a key component of executive and director compensation packages designed to align leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation to directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, typically over one to four years, is also common, ensuring continued commitment from the director.
• The use of a Rule 10b5-1 plan for such transactions is a best practice for insiders to manage their equity holdings in a compliant and transparent manner, consistent with corporate governance standards.

Corporate Governance

Related Party Transactions

• The grant of stock options to Edward T. Mathers, a Director and 10% Owner, constitutes a related party transaction, which is a standard form of compensation for company leadership.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved long-term value creation.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The stock options will vest based on the specified conditions (earlier of first anniversary of grant or 2026 Annual Meeting), subject to continued service.
• Edward T. Mathers may choose to exercise these options at any time after vesting and before the expiration date.

Key Dates

Keywords

Senti Biosciences, SNTI, stock option, insider transaction, Form 4, director compensation, equity grant, Rule 10b5-1